DelveInsight’s Triple Negative Breast Cancer Pipeline Insights Report lays out comprehensive insights about 10+ companies and 10+ pipeline drugs in the Triple Negative Breast Cancer competitive landscape. 

Key Players such as: AstraZeneca, Hoffmann-La Roche, Immunomedics, Merck, HiberCell, Infinity Pharmaceuticals, CytoDyn, etc., are involved in developing drugs for Triple Negative Breast Cancer.

TNBC-Pipeline

The TNBC Pipeline insights report offers a 360° view of the therapeutics landscape by:

  1. Development stage
  2. Product type
  3. Route of administration
  4. Molecule type
  5. Mechanism Of Action 

Triple-Negative Breast Cancer Overview:

Triple-Negative Breast Cancer is defined as the heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by IHC, or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

Through various secondary domains, it can be concluded that TNBC affects females.

For more insights into Disease, causes and treatment, reach out to Triple-Negative Breast Cancer Treatment Landscape.

Triple-Negative Breast Cancer Pipeline Therapies and Key Companies 

  • Lynparza: AstraZeneca
  • Tercentriq (Atezolizumab): Hoffmann-La Roche
  • Sacituzumab Govitecan-hziy: Immunomedics
  • Keytruda: Merck
  • Imprime PGG : HiberCell
  • Ipatasertib: Hoffmann-La Roche
  • IPI-549: Infinity Pharmaceuticals
  • Leronlimab (PRO 140): CytoDyn
  • And Many Others

For more information, visit Triple Negative Breast Cancer Market Analysis, Patient Pool and Emerging Therapies.

Reach out for more information: TNBC Drug Pipeline Assessment

Scope of the Report:

  1. Coverage: Global
  2. Key Market Players: AstraZeneca, Hoffmann-La Roche, Immunomedics, Merck, HiberCell, Infinity Pharmaceuticals, CytoDyn etc., and others,
  3. Key Pipeline Therapies: Lynparza, Tercentriq (Atezolizumab), Sacituzumab Govitecan-hziy, Keytruda, Imprime PGG, Ipatasertib, IPI-549, Leronlimab (PRO 140) and others.

Get in touch with our Business executive @ Triple Negative Breast Cancer Market Landscape Analysis.

Key Questions Answered:

  • How many firms are working on treatments for Triple Negative Breast Cancer?
  • How many Triple Negative Breast Cancer drugs does each company develop?
  • How many emerging drugs for Triple Negative Breast Cancer treatment are in mid-stage and late-stage development?
  • What are the most critical partnerships (industry–industry, industry-academia), mergers and acquisitions, and licencing activities related to TNBC therapeutics?
  • What are the latest developments, medication styles, and new technologies that have been created to address the limitations of current therapies?
  • What are clinical trials being conducted for Triple Negative Breast Cancer?
  • What are the most significant partnerships (industry–industry, industry-academia), mergers and acquisitions, and licencing activities involving TNBC therapeutics?
  • What are the latest developments, medication styles, and new technologies that have been created to address the limitations of current therapies?
  • What clinical trials are being conducted for Triple Negative Breast Cancer, and how far along are they?

Table of Contents 

1.

Report Introduction

2. 

Triple-Negative Breast Cancer

3. 

Triple-Negative Breast Cancer Current Treatment Patterns

4.

Triple-Negative Breast Cancer – DelveInsight’s Analytical Perspective

5.

Therapeutic Assessment

6.

Triple-Negative Breast Cancer Late Stage Products (Phase-III)

7.

Triple-Negative Breast Cancer Mid Stage Products (Phase-II)

8.

Early Stage Triple-Negative Breast Cancer Products (Phase-I)

9.

Triple-Negative Breast Cancer Pre-clinical Products and Discovery Stage Products

10.

Inactive Products

11.

Dormant Products

12.

Triple-Negative Breast Cancer Discontinued Products

13.

Triple-Negative Breast Cancer Product Profiles

14.

Triple-Negative Breast Cancer Key Companies

15.

Triple-Negative Breast Cancer Key Products

16.

Dormant and Discontinued Products

17.

Triple-Negative Breast Cancer Unmet Needs

18.

Triple-Negative Breast Cancer Future Perspectives

19.

Triple-Negative Breast Cancer Analyst Review

20.

Appendix

21.

Report Methodology

 

Learn more about the report offerings @ Triple Negative Breast Cancer Pipeline Therapies

Related Reports:

Her2 Negative Breast Cancer Market

 DelveInsight’s ‘Her2 Negative Breast Cancer Market Insights, Epidemiology and Market Forecast 2030′ report will provide Her2 Negative Breast Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Eisai, G1 Therapeutics, Genetech/La Roche, Sanofi, AstraZeneca and several others. 

Her2 Positive Breast Cancer Market

DelveInsight’s “Her2 Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030” report will provide Her2 Positive Breast Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Roche, Kadcyla, Genentech, Novartis, Puma Biotechnology, Seattle Genetics, MacroGenics, Prestige Biopharma, EirGenix, Roche, Genentech, Pfizer, Merck, Eli Lilly, Horizon Pharma and several others.

Her2 Positive Early Breast Cancer Market

DelveInsight’s ‘Her2 Positive Early Breast Cancer Market Insights, Epidemiology and Market Forecast – 2030‘ report will provide Her2 Positive Early Breast Cancer Market, Epidemiological and Therapeutics market domain.

Her2 Negative Metastatic Breast Cancer Market

DelveInsight’s “Her2 Negative Metastatic Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030” report. 

Metastatic Triple-Negative Breast Cancer Market

DelveInsight’s “Metastatic Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030” report will provide Metastatic Triple-Negative Breast Cancer Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Immunomedics, Merck, Roche, Pfizer, Astellas, Hoffman La Roche, Tesaro, AstraZeneca, Cytodyn and several others.

Brain Metastasis From Breast Cancer Pipeline

DelveInsight’s “Brain Metastasis from Breast Cancer Pipeline Insights, 2021,” report provides comprehensive insights about companies and pipeline drugs, including Angiochem, Northwest Biotherapeutics, Merck, Novartis Pharmaceuticals, Abbott, Ipsen, Puma Biotechnology, Cortese Biosciences, Onconova Therapeutics and several others. 

About DelveInsight 

DelveInsight is a leading Market Research, and Business Consultant focused purely on life sciences. It assists pharma companies by providing them with end-to-end solutions to boost their performance.

Get access to all the Pharma and healthcare market research reports through our market research subscription-based platform PharmDelve.

Connect With Us at:

LinkedIn | Facebook | Twitter

Get Free Sample Copy of Report at:

https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight